Bernard Charbonnel, professor of endocrinology and metabolic diseases at the University of Nantes in France, is one of five external members of a new clinical and scientific advisory board that has been set up by Zealand Pharma A/S to guide the company in its drug discovery and development work. The other members include, Richard Pratley, medical director of the Florida Hospital Diabetes Institute in the US ; Paul Dorian, department director of the University of Toronto’s Division of Cardiology in Canada; Åke Lernmark, professor of experimental diabetes at Lund University in Sweden and Gert Van Assche, professor of medicine at the University of Leuven in Belgium.
Copyright 2011 Evernow Publishing Ltd